

PTO/SB/088 (08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/810,388
	Filing Date	March 26, 2004
	First Named Inventor	SHAW et al.
	Art Unit	1614 1699
	Examiner Name	
Sheet 1 of 1	Attorney Docket Number	5853-400

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SO		HORNBECK et al., Enzyme-Linked Immunosorbent Assays, Current Protocols in Molecular Biol., 11.2.1-11.2.22 (1991)	
ll		Pierce Catalog, pgs. C-7, C-22, C-23, C-36, C-37 (1992)	
ll		POSMANTUR et al., Neurofilament 68 and Neurofilament 200 Protein Levels Decrease After Traumatic Brain Injury, J. of Neurotrauma, vol. 11, no. 5 (1994)	
ll		NYLEN et al., Cerebrospinal Fluid Neurofilament and Glial Fibrillary Acidic Protein in Patients with Cerebral Vasculitis, J. of Neuroscience Research, 67:844-851 (2002)	
ll		HU et al., Elevated Levels of Phosphorylated Neurofilament Proteins in Cerebrospinal Fluid of Alzheimer Disease Patients, Neuroscience Letters, 320:156-160 (2002)	


Examiner Signature	<i>Stephen Gucker</i>	Date Considered	1/5/06
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/810,388
Filing Date	March 26, 2004
First Named Inventor	SHAW et al.
Art Unit	1614 1649
Examiner Name	
Attorney Docket Number	5853-400

Sheet

1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
56		DELACOURTE et al. Study of the 10-nm-Filament Fraction Isolated During the Standard Microtubule Preparation: Biochem Journal. 1980, Vol 191, pages 543-546	
11		WEBER et al. Tissue Polypeptide Antigen (TPA) is Related to the Non-Epidermal Keratins 8, 18 and 19 Typical of Simple and Non-Squamous Epithelia: Re-evaluation of a Human Tumor Marker. The EMBO Journal. 1984, Vol. 3, No. 11, pages 2707-2714	
4		PERSSON et al. S-100 Protein and Neuron-Specific Enolase in Cerebrospinal Fluid and Serum: Markers of Cell Damage in Human Central Nervous System. Stroke. 1987, Vol. 18, No. 5, pages 911-918	
11		INGEBRIGTSEN et al. Biochemical Serum Markers of Traumatic Brain Injury. The Journal of Trauma Injury, Infection, and Critical Care. 2002, Vol. 52, pages 798-808	
11		BJORKLUND, B. Tissue Polypeptide Antigen (TPA): Biology, Biochemistry, Improved Assay Methodology, Clinical Significance in Cancer and Other Conditions, and Future Outlook. Antibiotics Chemotherapy. 1978, Vol. 22, pages 16-31	
11		TOGO et al. Tau Accumulation in Astrocytes in Progressive Supranuclear Palsy in a Degenerative rather than a Reactive Process. Acta Neuropathol. 2002, Vol. 104, pages 398-402	
11		NAM et al. Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins. Science. 2003, Vol. 301, pages 1884-1886	
11		ZEMLAN, et al. Quantification of Axonal Damage in Traumatic Brain Injury: Affinity Purification and Characterization of Cerebrospinal Fluid Tau Proteins. Journal of Neurochemistry. 1999, Vol. 72, No. 2, pages 741-750	
11		PIKE et al. Accumulation of Calpain and Caspase-3 Proteolytic Fragments of Brain-Derived II-Spectrin in Cerebral Spinal Fluid After Middle Cerebral Artery Occlusion in Rats. Journal of Cerebral Blood Flow and Metabolism. 2004, Vol. 24, No. 1, pages 98-106	

Examiner
Signature

Stephen Eucker

Date
Considered

1/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.